COUCH Health Finds Reasons Behind Underrepresentation of Ethnic Minorities in US & UK Trials
COUCH Health has released new research exploring reasons behind the underrepresentation of ethnic minorities in US & UK clinical trials. Also addressed are how clinical trial communication strategies can be improved to better engage people from diverse backgrounds and ethnicities.
COUCH Health’s research findings suggest that participation from ethnic minorities continues to be low, even while COVID-19 has raised awareness of the importance of clinical trials among potential recruits and as the pharmaceutical industry has begun to tackle its diversity and inclusion problem. Many participants expressed their mistrust in so-called Big-Pharma, concern about being exploited and dehumanized, suspicion over the financial motives of the pharmaceutical industry, and disparities in the quality of care they might receive.
This research follows on from a study based in the United Kingdom, which found a similar reluctance from ethnic minorities to participate in clinical trials in the country. Both studies make several recommendations for better engaging potential recruits, including reaching out to community leaders, building tailored communication strategies per ethnic group, and providing complete information and transparency at every stage of the process.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
